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The aim of the present study was to develop an olanzapine freeze-dried tablet (FDT). The solubility and 
dissolution rate of poorly water-soluble olanzapine was improved by preparing a freeze-dried tablet of 
olanzapine using the freeze-drying technique . The FDT was prepared by dispersing the drug in an aqueous 
solution of highly water-soluble carrier materials consisting of gelatin, glycine, and sorbitol. The mixture 
was poured in to the pockets of blister packs and then was subjected to freezing and lyophilisation. The 
FDT was characterised by DSC, XRD and SEM and was evaluated for saturation solubility and dissolution. 
The samples were stored in a stability chamber to investigate their physical stability. Results obtained 
by DSC and X-ray were analysed and showed the crystalline state of olanzapine in FDT transformation 
to the amorphous state during the formation of FDT. Scanning electron microscope (SEM) results 
suggest reduction in olanzapine particle size. The solubility of olanzapine from the FDT was observed 
to be nearly four and a half times greater than the pure drug. Results obtained from dissolution studies 
showed that olanzapine FDT significantly improved the dissolution rate of the drug compared with 
the physical mixture (PM) and the pure drug. More than 90% of olanzapine in FDT dissolved within 
5 minutes, compared to only 19.78% of olanzapine pure drug dissolved over the course of 60 minutes. 
In a stability test, the release profile of the FDT was unchanged, as compared to the freshly prepared 
FDT after 90 days of storing. 
Uniterms: Freeze-dried tablets/development. Olanzapine/freeze-dried tablets. Olanzapine/solubility. 
Olanzapine/stability. Olanzapine/dissolution. Freeze-drying. 
O objetivo do presente estudo foi desenvolver comprimidos liofilizados de olanzapina (FDT). A 
solubilidade e a taxa de dissolução da olanzapina, fracamente solúvel em água, foram melhoradas com 
a preparação de comprimidos liofilizados de olanzapina usando a técnica de liofilização. O FDT foi 
preparado por dispersão do fármaco em solução aquosa de materiais altamente solúveis em água, como 
gelatina, glicina e sorbitol. A mistura foi colocada em blisters e, então, submetida ao congelamento 
e liofilização. O FDT foi caracterizado por DSC, Difração de Raios X e microscopia eletrônica de 
varredura(SEM) e avaliaram-se a solubilidade de saturação e a dissolução. As amostras for5am 
armazenadas em câmara de estabilidade para investigar a estabilidade física. Os resultados obtidos com 
DSC e Raios X foram analisados e mostraram a transformação do estado cristalino da olanzepina em FDT 
no estado amorfo durante a formação do FDT. Os resultados da SEM sugerem a redução do tamanho das 
partículas de olanzapina. A solubilidade da olanzapina do FDT melhorou significativamente a taxa de 
dissolução do fármaco comparativamente à mistura física (PM) e ao fármaco puro. Mais do que 90% da 
olanzepina no FDT dissolveu em 5 minutos, comparativamente aos 19,78% do fármaco puro dissolvido 
em 60 minutos. No teste de estabilidade, o perfil de liberação da FDT mostrou-se inalterado, quando 
comparado com o FDT recém-preparado, após 90 dias de armazenamento. 
Unitermos: Comprimidos liofilizados/desenvolvimento. Olanzapina/comprimidos liofilizados. 
Olanzapina/solubilidade. Olanzapina/estabalidade. Olanzapina/dissolução. Liofilização. 
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INTRODUCTION
O l a n z a p i n e ,  2 - m e t h y l - 4 - ( 4 - m e t h y l -
1-piperazinyl)-10H-thieno-[2, 3b], [1, 5] benzodiazepine 
is a potent antipsychotic agent. As a free base or its hydro-
chloride salt, olanzapine is an active ingredient of pharma-
ceutical preparations used in the treatment of disorders of 
the central nervous system. Olanzapine belong to class II 
category under the biopharmaceutical classification sys-
tem (BCS), i.e., it is inherently highly permeable through 
biological membranes, but exhibits low aqueous solubil-
ity. Rate of absorption and/or extent of bioavailability for 
such insoluble hydrophobic drug are controlled by rate of 
dissolution in gastro-intestinal fluids. However, its oral 
bioavailability is very low, probably due to poor solubility 
in water and insufficient dissolution rate (Aarsland et. al., 
1999; Adams et al., 1999; Almeida et al., 1998).
Currently, several approaches are widely used to 
fabricate rapid dissolving tablets (RDT), including lyophi-
lisation, solid dispersion, mucoadhesive micro-particulate, 
direct compression, and moulding. Therefore, several 
solubilisation techniques have been applied and reported 
to enhance the aqueous solubility of poorly water-soluble 
drugs, therefore there is some literature available on 
enhancing the solubility and dissolution of olanzapine, 
such as Orally Disintegrating Tablets of Olanzapine 
2-Hydroxypropyl-β-Cyclodextrin Inclusion Complex 
(Ajit et al., 2010), Characterization of Olanzapine-Solid 
Dispersions (Venkateskumar et al., 2011), Formulation 
and evaluation of Olanzapine as Orodispersible drug 
delivery system of Olanzapine using beta cyclodextrin 
and super disintegrant (Sarath et al., 2011). There are 
also methods available for other water insoluble drugs, 
such as Formation of Solid Dispersions of mefenamic 
acid with crospovidone (Nagabhushanam et al., 2011), 
and Formation of mefenamic acid capsule with sodium 
lauryl sulphate (Pradnya et al., 2010), The Fast-dissolving 
mucoadhesive micro-particulate containing piroxicam 
(Francesco et al. 2005). The formation of a piroxicam acid 
fast dissolving tablet has also been proposed (Modasiya et 
al., 2009; Bhupendra et al., 2010). However, in terms of 
sales value, sales volume and number of products available 
on the market, the freeze-drying (lyophilisation) method 
has been the most successful (Muir, 2007). The fabrication 
of freeze-drying RDT is based on creating a porous matrix 
by subliming the water from the pre-frozen aqueous for-
mulation of the drug containing matrix forming agents and 
other excipients, such as preservatives, flavors and lyo-
protectants (Segar, 1998). The matrix of the freeze-drying 
RDT consists of two components that work together to 
ensure the development of a successful formulation. The 
first component consists of water-soluble polymers, such 
as gelatin, dextrin, alginate and maltodextrin (Corveleyn 
et al., 1998; Chandrasekhar et al., 2009). This component 
maintains the shape and provides mechanical strength to 
the tablets (binder). The second constituent consists of 
matrix-supporting/disintegration-enhancing agents, such 
as sucrose and mannitol, which act by cementing the po-
rous framework provided by the water-soluble polymer 
and accelerate the disintegration of the RDT (Farhan et 
al., 2010). Although there is wide availability of literature 
describing the preparation of RDT by freeze-drying, the 
number of matrix-supporting/disintegration-enhancing 
agents used has been limited to saccharides and polyols, 
with the majority of the work dedicated to the inclusion 
of mannitol (Segar, 1998; Corveleyn et al., 1998; Farhan 
et al., 2010). This is primarily because the incorpora-
tion of these matrix-forming agents requires fulfillment 
of stringent characteristics, such as reasonable drying 
time and stability during freeze-drying process, as well 
as formation of elegant tablets with short disintegration 
time and adequate mechanical properties. However, 
a high concentration of saccharides and polyols is re-
quired to achieve these quality features (Segar, 1998; 
Chandrasekhar et al., 2009; Farhan et al., 2010), thus 
restraining their application in delivering drugs for the 
treatment of long-term chronic conditions, especially for 
children, diabetic and obese patients, due to the require-
ment of limited intake of saccharides and polyols. There-
fore, the present study aims to develop novel excipients 
by investigating the feasibility of using amino acids as 
matrix-supporting agents (second component) for the 
fabrication of RDT prepared by freeze-drying, in order to 
produce tablets with enhanced properties and wider ap-
plication to the pediatric and geriatric patient population.
In this present study to prepare olanzapine FDT, 
DSC, XRD, and SEM analyses were performed to de-
termine the physicochemical properties of the FDT and 
then compare these properties with those of the physical 
mixture (PM) and pure drug, determining the saturated 
solubility and dissolution characteristics of olanzapine in 
the prepared FDT.
MATERIAL AND METHODS
Material
Olanzapine was gifted by Micro Labs, Bangalore, 
India. Micronised gelatin, glycine, and sorbitol were gifted 
by IPCA Pharmaceutical Ltd., Mumbai, India. All the wa-
ter used was distilled de-ionised water. All other materials 
used were analytical grade.
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Method
Preparation of olanzapine freeze-dried tablets
This method consisted of the following steps: A 
2% w/v solution of gelatin in water was prepared, by first 
soaking the gelatin in water until complete hydration. 
The hydrated gelatin was then stirred using a magnetic 
stirrer until a clear solution was obtained. Equal weights 
of glycine (0.886% w/v) and sorbitol (0.886% w/v) were 
added to the gelatin solution while stirring until complete 
dissolution. An accurately weighed amount of olanzapine 
powder (2.5% w/v) was then dispersed in the aqueous 
solution of gelatin, glycine, and sorbitol. The resulting 
suspension above was poured into a tablet blister (1 ml into 
each of the pockets), resulting in an olanzapine dose of 25 
mg per tablet. The tablet blister packs, each pack contain-
ing 8 tablets, were then transferred to an ultra low freezer 
at -40 °C and kept in the freezer for 24 hours. The frozen 
tablets were placed in a lyophiliser for 24 hours using a 
Freeze Dryer (IISHIN Lab. Co. Ltd. Korea) with a con-
denser temperature of -400C and a pressure of 7×10-2 mbar, 
followed by a secondary drying at 25 0C for 12 hours. The 
FDT were kept at a desiccator’s room temperature until 
further experiment. Five blister packs containing a total 
of 40 tablets were produced in each run. Eight tablets 
were randomly selected for drug content uniformity. The 
mean percentage drug content was found to be 99.54% ± 
0.014%.
Preparation of PM
The olanzapine was uniformly mixed with gelatin, 
glycine and sorbitol in the same percentage used in the 
FDT using a mortar and pestle. The prepared mixtures 
were kept in desiccators until further use.
Determination of drug content
The FDT were triturated with 10 mL of water and 
allowed to rest for 10 minutes with occasional swirling, 
and water was then added to produce 100 mL. After suit-
able dilution, 10 mL of the solution were taken and filtered 
through a membrane filter (0.45 µm), and the amount of 
dissolved drug was measured at 250 nm using the UV 
spectrophotometric method. Drug content was determined 
from a standard plot. Sampling was performed in triplicate.
Differential scanning calorimetry 
A differential scanning calorimetry (DSC) study was 
carried out to detect possible polymorphic transition dur-
ing the crystallisation process. DSC measurements were 
performed on a DSC DuPont 9900 differential scanning 
calorimeter using a thermal analyzer.
X-ray diffraction analysis
X-Ray powder diffraction patterns were obtained 
at room temperature using a Philips X’ Pert MPD dif-
fractometer, using Cu as anode material and a graphite 
monochromator, operated at a voltage of 40 mA, 45 kV. 
The process parameters used were set as a scan step size 
of 0.0170 (2q).
Scanning electron microscopy 
Scanning electron microscopic (Joel- LV-5600, 
USA, with magnification of 250x) photographs were 
obtained to identify and confirm the spherical nature and 
Surface topography of the crystals.
Solubility studies
Olanzapine (100 mg), its FDT, and PM equivalent to 
100 mg of olanzapine were placed in glass stopper flasks 
and then shaken in a water bath at 37 oC for 48 hours. The 
solutions were filtered through a membrane filter (0.45 µg) 
and the dissolved drug was then measured spectrophoto-
metrically at 250 nm. Each sample was done in triplicate.
Dissolution studies
The dissolution profile of pure olanzapine compared 
with the PM and FDT were determined by using a USP 
dissolution apparatus XXIV-Type II (Electro Lab, Mum-
bai). All tests were conducted in 900 ml of distilled water 
maintained at 37 ± 0.2o C with a paddle rotation speed of 
100 rpm. After specified time intervals, samples of dis-
solution medium were withdrawn and replaced with an 
equal amount of fresh medium to maintain sink condi-
tions and then filtered. The amount of dissolved drug was 
determined using a UV spectrophotometric method (UV 
1601 A Shimadzu, Japan) at 250 nm (Venkateskumar et 
al., 2011). Each sample was done in triplicate.
Determination of physical stability
To determine the physical stability of the FDT, 
tablets were placed in a climate chamber at 20 oC with 
45% of relative humidity (RH). After 90 days, the drug 
release percentage of olanzapine in the FDT sample was 
determined by a dissolution study and compared to freshly 
prepared FDT.
RESULTS AND DISCUSSIONS
In the preparation of olanzapine FDT, different 
fast-dissolving carrier materials were used. Among them, 
glycine was used to prevent shrinkage of the tablet during 
manufacturing, possibly due to the plasticising effect of 
lysine. This is in line with previously reported research, 
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which has shown that, in freeze-dried systems, inclusion 
of solutes within the formulation results in lowering of 
the glass transition temperature and is dependent on the 
interactions between the added excipient and unfrozen 
water. Sorbitol, used to impart crystallinity, hardness, 
and elegance to the tablet, is a well-known and accept-
able material for use in preparing freeze-dried tablets. 
The percentage of excipients used was optimised during 
the formulation process to result in a strong and elegant 
tablet that could be handled with ease (Farhan et al., 2010).
Figure 1 shows the DSC curves obtained for pure 
olanzapine, PM, and FDT. The DSC analysis was carried 
out to evaluate the crystalline properties of olanzapine in 
FDT, PM, and in the pure drug, In the DSC curve, pure 
olanzapine had a sharp endothermic peak at 194 °C, which 
corresponded to the melting point of olanzapine (Ajit et 
al., 2010). The thermogram of the PM showed the endo-
thermic peak of olanzapine, although broader, spitted, and 
slightly shifted to the left, thus indicating that the crystal-
line state is maintained but decreased in the PM, and it also 
showed a sharp endothermic peak at 193 °C. However, the 
melting endotherm was absent on the DSC thermogram for 
the FDT, suggesting absence of crystallinity and presence 
of an amorphous state of the drug. This could be because 
olanzapine was molecularly or amorphously dispersed in 
the freeze-dried tablet (FDT).
X-Ray diffraction was used to analyze potential 
changes in the inner structure of olanzapine nanocrystals 
during the formulation of the FDT. The extent of such 
changes depends on the chemical nature and physical 
hardness of the active ingredient. The powder X-ray dif-
fraction patterns of the pure drug, PM, and FDT are shown 
in Figure 2. The results of the DSC were further conformed 
by X-ray diffraction studies (Figure 2). The characteristic 
peak of the olanzapine appeared in the 2θ range of 10–30o, 
thus indicating that the unprocessed olanzapine was a crys-
talline material (Ajit et al., 2010). The pure drug exhibits 
its characteristic diffraction peaks at various diffraction 
angles, thus indicating the presence of crystallinity. The 
X-ray diffraction study of the drug and excipients PM 
showed the peak corresponding to the crystalline drug 
molecules present in the mixture, although their intensity 
was lower due to the high excipients-drug ratio employed. 
The diffraction pattern of the drug FDT showed absence, 
broadening and reduction of major olanzapine diffraction 
peaks, thus indicating that the FDT contained mostly an 
amorphous form (disordered state). These results could 
explain the observed enhancement of solubility and rapid 
dissolution of olanzapine in FDT.
Scanning electron microscope (SEM) micrographs 
of pure olanzapine, PM, and FDT are shown in Figure 3. 
Results showed that olanzapine crystals could be seen in 
the PM, while the micrograph of FDT shows a matrix in 
which no crystals of olanzapine could be seen. The SEM 
micrograph of FDT suggests that the particles of the drug 
might have been reduced during dissolution in the gelatin-
FIGURE 1 - DSC spectrum of Olanzapine samples.
FIGURE 2 - X-ray powder diffraction spectrum of Olanzapine 
samples.
FIGURE 3 - Scanning electron micrographs of Olanzapine 
samples.
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glycine-sorbitol solution. This could, therefore, indicate 
that olanzapine particle size has been reduced, which also 
accelerates solubility and dissolution.
Increase in the solubility of olanzapine from FDT 
(0.1283 mg/mL) was found to be nearly four times higher 
than the solubility of the pure drug (0.0343 mg/mL), sug-
gesting the presence of a high amount of an amorphous 
form of olanzapine in the FDT, indicating super-saturation 
obtained from the FDT. Increase in the solubility of 
olanzapine from the PM (0.0831 mg/mL) was more than 
two times that of the pure drug. This could be due to the 
solubilising effect of highly water-soluble carrier materials 
used in the formulation, such as glycine and sorbitol. The 
solubility results for the different formulations are shown 
in Table I. The higher solubility of olanzapine from FDT 
may be due to the increased surface area, wettability and 
solubilising effect of highly water-soluble carrier materials 
used in the formulations.
The dissolution curves of olanzapine in distilled 
water are shown in Figure 4. The dissolution rate profiles 
were plotted as the percentage release from the FDT, PM, 
and pure olanzapine versus time in minutes. The rate of 
dissolution of pure olanzapine was slow, compared to that 
of PM and FDT. Olanzapine in the FDT was immediately 
dispersed and almost completely dissolved (95.37 %) in 5 
minutes. Initial dissolution rate of olanzapine in the FDT 
TABLE I - Solubility of olanzapine as pure drug, PM and FDT 
in distilled water at 37 °C
Olanzapine samples 
(mg/mL)
Solubility mg/mL 
(± SD, n=3)
Pure olanzapine 0.0343 ±0.011
PM 0.0831 ±0.015
FDT 0.1283 ±0.013
FIGURE 4 - Dissolution profiles for olanzapine as pure drug, 
PM and FDT in distilled water at 37 °C.
increased markedly about twenty-one-fold in 5 minutes, 
compared to that of pure olanzapine. The dissolution rate 
was also higher and faster in FDT than in PM. The percent-
age of olanzapine dissolved from the PM in 60 minutes 
(70.83 %) increased approximately four-fold, when com-
pared to pure olanzapine alone (19.78 %).
Enhancement in the solubility and dissolution rates 
of olanzapine FDT may be attributed to the formation of 
an amorphous state of fast dissolving carrier materials in 
the FDT (Farhan et al., 2010).
The dissolution behavior of olanzapine FDT must re-
main unchanged during storage. The best way to guarantee 
this is by maintaining their physical state and molecular 
structure. For optimal stability of amorphous FDT, mo-
lecular mobility should be as low as possible. However, 
partially or fully amorphous FDT are thermodynamically 
unstable and will have a natural tendency to crystallise, 
because the crystalline state has lower energy, when 
compared to amorphous material. However, amorphous 
material can be kinetically stable, which implies that the 
equilibrium state, i.e. crystalline, is not reached within the 
timeframe of the experiment or shelf life of the product. 
Therefore, the physical state should be monitored, because 
changes therein are likely to alter drug release (Crowe et 
al., 2000) and this can also be monitored by determining 
the crystallinity percentage in the samples, by means of 
DSC (Nazik et al., 2010).
The results of the stability study for FDT stored at 
20o C with 45% of RH for 90 days are shown in Figure 5. 
The influence of FDT on the physical stability of olan-
zapine was investigated. The percentage of drug release 
from FDT was almost the same (99.54%) after 90 days of 
storage, when compared to freshly prepared FDT (99.62%) 
FIGURE 5 - Stability dissolution profiles of olanzapine samples. 
FDT A - Fresh FDT; FDT B - FDT after 90 days of storage.
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after 60 minutes. The results above showed that olanzap-
ine FDT was stable after 90 days of storage at 20 °C with 
45% of RH.
The DSC study for physical stability revealed the 
crystalline and amorphous state of the drug in the FDT 
(Figure 6). As no change in the DSC thermograph was 
observed during the storage period, the DSC study could 
provide sufficient evidence to support that there was no 
change in the amorphous form of the drug in the FDT.
CONCLUSION
This present study revealed that the successful 
formulation of olanzapine FDT made with widely used, 
safe, water-soluble excipients is feasible for enhancing 
the solubility and dissolution rate of olanzapine. Since 
the results obtained were attributed to the formation of an 
amorphous state of the olanzapine FDT and probability to 
reduction of the olanzapine particle size. The physical sta-
bility results for the FDT showed that the FDT was stable, 
and release from the FDT was almost unchanged after 90 
days. Based on these results, it can be concluded that the 
olanzapine FDT could be suitable in terms of solubility and 
dissolution in water. This technique provides a promising 
manufacturing procedure for the formulation of olanzapine 
tablets by direct compression with directly compressible 
tablet excipients, without mixing or formulation steps. 
Moreover, the properties of the tablet are suitable for 
enhancing bioavailability.
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